招商国证生物医药指数(LOF)C(012417)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-188,667,534.98 |
-319,646,675.74 |
-157,691,402.88 |
-184,064,892.67 |
| 本期利润 |
38,989,900.23 |
-514,120,339.14 |
-627,455,247.04 |
-415,750,512.13 |
| 加权平均基金份额本期利润 |
0.01 |
-0.11 |
-0.14 |
-0.11 |
| 本期加权平均净值利润率(%) |
2.14 |
-27.49 |
-33.94 |
-20.92 |
| 本期基金份额净值增长率(%) |
1.85 |
-22.96 |
-27.60 |
-20.25 |
| 期末可供分配利润 |
-2,696,922,526.17 |
-3,296,475,165.29 |
-3,387,035,754.21 |
-2,246,107,182.04 |
| 期末可供分配基金份额利润 |
-0.62 |
-0.63 |
-0.65 |
-0.51 |
| 期末基金资产净值 |
1,657,845,015.51 |
1,968,160,494.02 |
1,834,010,314.45 |
2,117,164,175.13 |
| 期末基金份额净值 |
0.38 |
0.37 |
0.35 |
0.49 |
| 基金份额累计净值增长率(%) |
-65.75 |
-66.37 |
-68.39 |
-56.35 |
微信公众号
证券之星APP
基本资料
